Nephrotoxicity of high-dose gadolinium compared with iodinated contrast

Journal of Magnetic Resonance Imaging

Volumn 6, Issue 1, 1996, Pages 162-166

  Prince, Martin R ^a   Arnoldus, Christina ^a   Frisoli, Joan K ^a  

^a NONE

Author keywords

Angiography; Gadolinium; Hypertension; Iodine; Kidney; Renal

Indexed keywords

CHELATING AGENT; CONTRAST MEDIUM; CREATININE; GADOLINIUM; IODINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; CHILD; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; HUMAN; KIDNEY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHELATING AGENTS; CHILD; CHILD, PRESCHOOL; CONTRAST MEDIA; CREATININE; FEMALE; GADOLINIUM; HUMANS; IODINE COMPOUNDS; KIDNEY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED;

EID: 0029680085     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmri.1880060129     Document Type: Article

References (27)

1. Harpur ES, Worah D, Hals, P, Holtz E, Furuhama K, Nomura H. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest Radiol 1993; 28:S28-S43.
2. Leander P, Allard M, Caille JM, Golman K. Early effect of gadopentate and iodinated contrast media on rabbit kidneys. Invest Radiol 1992; 27:922-926.
3. Carvlin MJ, DeSimone DN, Meeks MJ. Phase II clinical trial of gadoteridol injection, a low-osmolal magnetic resonance imaging contrast agent. Invest Radiol 1992; 27:S16-S21.
4. Goldstein HA, Kashanian FK, Blumetti RF, Holyoak WL, Hugo FP, Blumenfield DM. Safety assessment of gadopentetate dimeglumine in U.S. clinical trials. Radiology 1990; 174:17-23.
5. Haustein J, Niendorf HP, Krestin G, et al. Renal tolerance of gadolinium-DTPA/dimeglumine in patients with chronic renal failure. Invest Radiol 1993; 27:153-156.
6. Lufkin RB. Severe anaphylactoid reaction to Gd-DTPA (letter to the editor). Radiology 1990; 176:879.
7. Lundby B, Berg KJ, Lien HH, Aamdal S. A double blind study to evaluate the tolerability of gadodiamide injection and its effect on renal function in patients undergoing cerebral magnetic resonance imaging. Br J Radiol 1993; 66:871-876.
8. Niendorf HP, Dinger JC, Haustein J, Cornelius I, Alhassan A, Clauss W. Tolerance data of Gd-DTPA: a review. Eur J Radiol 1991; 13:15-20.
9. Niendorf HP, Haustein J, Cornelius I, Alhassan A, Clauss W. Safety of gadolinium-DTPA: extended clinical experience. Magn Reson Med 1991; 22:222-228.
10. Niendorf HP, Haustein J, Louton T, Beck W, Laniado M. Safety and tolerance after intravenous administration of 0.3 mmol/kg Gd-DTPA. Results of a randomized, controlled clinical trial. Invest Radiol 1991; 26:S221-S223.
11. Rofsky NM, Weinreb JC, Bosniak MA, Libes RB, Birnbaum BA. Renal lesion characterization with gadolinium-enhanced MR imaging: efficacy and safety in patients with renal insufficiency. Radiology 1993; 180:85-89.
12. Runge VM, Bradley WG, Brant-Zawadzki MN, et al. Clinical safety and efficacy of gadoteridol: a study in 411 patients with suspected intracranial and spinal disease. Radiology 1991; 181: 701-709.
13. Schuhmann-Giampieri G, Krestin G. Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Invest Radiol 1991; 26:975-979.
14. Rofsky NM, Weinreb JC, Bosniak MA, Libes RB, Birnbaum BA. Renal lesion characterization with gadolinium-enhanced MR imaging: efficacy and safety in patients with renal insufficiency. Radiology 1991; 180:85-89.
15. Runge VM, Kirsch JE, Thomas GS. High-dose applications of gadolinium chelates in magnetic resonance imaging. Magn Reson Med 1991; 22:358-363.
16. Prince MR. Gadolinium-enhanced MR Aortography. Radiology 1994; 191:155-164.
17. Arrigo G, Cavaliere G, Scalia A, et al. Radiocontrast media nephrotoxicity: clinical aspects. Contrib Nephrol 1987; 55:176-188.
18. Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K. Adverse reactions to ionic and nonionic contrast media: a report from the Japanese Committee on the Safety of Contrast Media. Radiology 1990; 175:621-628.
19. Parfrey PS, Griffiths SM, Barrett BJ, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both: a prospective controlled study. N Engl J Med 1989; 320:143-149.
20. Schwab SJ, Hlatky MA, Pieper KS, et al. Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. N Engl J Med 1989; 320:149-153.
21. Rocklage SM, Woran D, Kim S. Metal ion release from paramagnetic chelates: what is tolerable? Magn. Reson. Med. 1991; 21:216-221.
22. Oksendal AN, Hals P. Biodistribution and toxicity of MR contrast media. JMRI 1993; 3:157-165.
23. Berlex Laboratories, Inc. Package insert: Magnevist injection (brand of gadopentetate dimeglumine). Wayne, NJ: Berlex Laboratories, Inc., 1988.
24. Kinno Y, Odagiri K, Andoh K, Itoh Y, Tarao K. Gadopentetate dimeglumine as an alternative contrast material for use in angiography. Am J Roentgenol 1993; 160:1293-1294.
25. Quinn AD, O'Hare NJ, Wallis FJ, Wilson GF. Gd-DTPA: an alternative contrast medium for CT. J Comput Assist Tomogr 1994; 18:634-636.
26. Weiss KL. Severe anaphylactoid reaction after IV Gd-DPTA. Magn Reson Imaging 1990; 8:817-818.
27. Jordan RM, Mintz RD. Fatal reaction to gadopentetate dimeglumine. Am J Roentgenol 1995; 164:743-744.